000520 — Samil Pharmaceutical Co Income Statement
0.000.00%
- KR₩170bn
- KR₩323bn
- KR₩196bn
- 15
- 55
- 14
- 14
Annual income statement for Samil Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 121,107 | 122,999 | 134,247 | 179,676 | 196,346 |
Cost of Revenue | |||||
Gross Profit | 46,724 | 49,032 | 48,988 | 67,486 | 74,071 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 116,284 | 116,461 | 133,847 | 175,656 | 190,458 |
Operating Profit | 4,823 | 6,538 | 400 | 4,020 | 5,888 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,456 | 1,198 | -4,761 | 1,058 | 1,424 |
Provision for Income Taxes | |||||
Net Income After Taxes | 786 | 1,341 | -5,347 | -28.3 | 1,664 |
Net Income Before Extraordinary Items | |||||
Net Income | 786 | 1,341 | -5,347 | -28.3 | 1,664 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 786 | 1,341 | -5,347 | -28.3 | 1,664 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 57.8 | 101 | -404 | -10.4 | 65.3 |
Dividends per Share |